Debiopharm S.A.
http://www.debiopharm.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Debiopharm S.A.
Ligand Makes Second Big Oncology Investment In 2024 With Apeiron Buyout
The company is acquiring rights to royalties from Qarziba, a neuroblastoma drug approved in ex-US markets that Recordati develops and markets in all of them except mainland China.
Finance Watch: SPACs Attempt A Comeback Ahead Of Full IPO Recovery
Public Company Edition: Several special purpose acquisition corporations have emerged, including various health care- and life science-focused SPACs. Also, Alvotech entered into a $965m refinancing agreement and Avidity grossed $461m in a follow-on offering, among other updates.
Asia Deal Watch: Chugai Extends Relationship With Helsinn
Plus deals involving Kissei/JWP, Shionogi/Cilcare, Takeda/Torrent, Genome & Co./Debiopharm, Kaken/J&J, CStone/Ewopharma, MediLink/BioNTech and more.
UroGen UGN-102 Impresses On Durability Data
The company announced strong durability data at 12 months for patients with low-grade intermediate risk non-muscle invasive bladder cancer treated with UGN-102.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
- Other Names / Subsidiaries
-
- H3 Pharma
- Affinium Pharmaceuticals, Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice